Loading...
Docoh

Arrowhead Pharmaceuticals (ARWR)

Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep, and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Arrowhead's RNAi-based therapeutics leverage this natural pathway of gene silencing.

Company profile

Ticker
ARWR
Exchange
CEO
Christopher Anzalone
Employees
Incorporated
Location
Fiscal year end
Former names
ARROWHEAD RESEARCH CORP, INTERACTIVE GROUP INC, INTERACTIVE INC
SEC CIK
Subsidiaries
Arrowhead Madison Inc. • Arrowhead Australia Pty Ltd ...
IRS number
460408024

ARWR stock data

Investment data

Data from SEC filings
Securities sold
Number of investors

Calendar

10 May 22
26 Jun 22
30 Sep 22
Quarter (USD) Mar 22 Dec 21 Sep 21 Jun 21
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD) Sep 21 Sep 20 Sep 19 Sep 18
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Cash burn rate (est.) Burn method: Change in cash Burn method: Operating income Burn method: FCF (opex + capex)
Last Q Avg 4Q Last Q Avg 4Q Last Q Avg 4Q
Cash on hand (at last report) 86.41M 86.41M 86.41M 86.41M 86.41M 86.41M
Cash burn (monthly) 1.73M 23.83M (no burn) 9.64M (no burn) 4.36M
Cash used (since last report) 4.96M 68.42M n/a 27.69M n/a 12.52M
Cash remaining 81.45M 17.98M n/a 58.72M n/a 73.88M
Runway (months of cash) 47.2 0.8 n/a 6.1 n/a 16.9

Beta Read what these cash burn values mean

Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
11 Feb 22 Anzalone Christopher Richard Common Stock Sell Dispose S No Yes 50.51 1,900 95.97K 4,057,634
11 Feb 22 Anzalone Christopher Richard Common Stock Sell Dispose S No Yes 50.9 61,482 3.13M 4,059,534
11 Feb 22 Anzalone Christopher Richard Common Stock Sell Dispose S No Yes 52.28 42,153 2.2M 4,121,016
11 Feb 22 Anzalone Christopher Richard Common Stock Sell Dispose S No Yes 53.11 40,853 2.17M 4,163,169
11 Feb 22 Anzalone Christopher Richard Common Stock Option exercise Acquire M No Yes 5.19 146,388 759.75K 4,204,022
11 Feb 22 Anzalone Christopher Richard Stock Option (right to buy Common Stock) Common Stock Option exercise Dispose M No No 5.19 146,388 759.75K 615,033
7 Jan 22 Backer Marianne De Common Stock Grant Acquire A No No 0 6,400 0 23,400
7 Jan 22 Mauro Ferrari Common Stock Grant Acquire A No No 0 6,400 0 42,971
7 Jan 22 Given Douglas B Common Stock Grant Acquire A No No 0 6,400 0 116,268
64.5% owned by funds/institutions
13F holders Current Prev Q Change
Total holders 300 310 -3.2%
Opened positions 37 51 -27.5%
Closed positions 47 34 +38.2%
Increased positions 115 102 +12.7%
Reduced positions 100 110 -9.1%
13F shares Current Prev Q Change
Total value 3.14B 4.52B -30.6%
Total shares 68.17M 68.17M +0.0%
Total puts 467.2K 481.71K -3.0%
Total calls 392.6K 892.7K -56.0%
Total put/call ratio 1.2 0.5 +120.5%
Largest owners Shares Value Change
BLK Blackrock 12.16M $559.01M +1.2%
Vanguard 9.72M $446.94M +0.8%
STT State Street 4.68M $215.32M +19.9%
JPM JPMorgan Chase & Co. 2.92M $134.33M -2.0%
Alliancebernstein 2.76M $126.76M +11.8%
IVZ Invesco 2.33M $107.35M +1.2%
Geode Capital Management 1.85M $85.31M +2.1%
FMR 1.4M $64.32M +2.4%
NTRS Northern Trust 1.39M $63.72M -2.6%
CS Credit Suisse 1.28M $58.66M +1.0%
Largest transactions Shares Bought/sold Change
JNJ Johnson & Johnson 1.26M -2M -61.3%
STT State Street 4.68M +777.18K +19.9%
Norges Bank 0 -690.82K EXIT
Point72 Asset Management 561.1K +516.81K +1166.8%
Caas Capital Management 484.85K +484.85K NEW
Renaissance Technologies 380.3K +380.3K NEW
Aquilo Capital Management 1.05M +347.01K +49.5%
RTW Investments 0 -346.84K EXIT
L1 Capital Pty 0 -292.74K EXIT
Alliancebernstein 2.76M +291.82K +11.8%

Financial report summary

?
Risks
  • Our success depends on the attraction and retention of senior management and scientists with relevant expertise.
  • Geopolitical risks associated with the ongoing Russia-Ukraine conflict have impacted our clinical trial plans and could have an adverse impact on our business, financial condition and results of operations.
  • Our ability to protect our patents and other proprietary rights is uncertain, exposing us to the possible loss of competitive advantage.
Management Discussion
  • The increase in revenue and operating income for the three and six months ended March 31, 2022 compared to the three and six months ended March 31, 2021 was driven by the revenue recognized from the GSK, Takeda and Horizon License Agreements.

Content analysis

?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. sophomore Avg
New words: abroad, adequately, advantage, afford, amplify, aspect, Asthma, attract, attraction, breadth, chain, concept, conflict, credit, culture, curtail, decided, decline, defending, derive, desirable, difficulty, diminished, distracting, duration, economy, employment, encounter, enforce, enforceable, EU, Europe, evolving, expertise, exposing, extent, feasible, footprint, forced, foreign, frustrate, GATEWAY, Geopolitical, hire, Hong, hypercholersterolemia, impair, impairment, imposed, industry, inflationary, infringe, innovative, invalidated, invention, ix, joint, Kong, landscape, Macau, macroeconomic, magnitude, mainland, maintain, maintenance, managerial, meaningful, parallel, pressure, proof, proprietary, prosecution, protect, protecting, prove, qualified, RCC, receipt, reduction, remote, repair, retaliatory, retention, Russia, shut, siRNA, sought, sponsored, stake, stemming, superior, Taiwan, technical, Ukraine, unable, uncertain, uncertainty, unenforceable, unexercised, unforeseen, venture, vii, viii, Visirna, Vivo, workplace, world, xi
Removed: begun, carcinoma, cell, disorder, obstructive, renal